Atypical Antipsychotics and Metabolic Syndrome: From Molecular Mechanisms to Clinical Differences

20‐year follow‐up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)

(2020) Heidi Taipale et al.   World Psychiatry

New roles for dopamine D2 and D3 receptors in pancreatic beta cell insulin secretion

(2019) Zachary J. Farino et al.   MOLECULAR PSYCHIATRY

Emerging Roles for Serotonin in Regulating Metabolism: New Implications for an Ancient Molecule

(2019) Julian M Yabut et al.   ENDOCRINE REVIEWS

Genetic deletion of β2 adrenergic receptors exacerbates hepatocellular lipid accumulation in high-fat diet mice

(2019) Xiang Tao et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Simvastatin improves olanzapine-induced dyslipidemia in rats through inhibiting hepatic mTOR signaling pathway

(2019) Xue-mei Liu et al.   ACTA PHARMACOLOGICA SINICA

Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone

(2019) Filippo Corponi et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Glucagon Receptor Signaling and Glucagon Resistance

(2019) Janah et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis

(2019) Maximilian Huhn et al.   LANCET

Insulin and β-adrenergic receptors mediate lipolytic and anti-lipolytic signalling that is not altered by type 2 diabetes in human adipocytes

(2019) Cecilia Jönsson et al.   BIOCHEMICAL JOURNAL

The epistatic interaction between the dopamine D3 receptor and dysbindin-1 modulates higher-order cognitive functions in mice and humans

(2019) G. M. Leggio et al.   MOLECULAR PSYCHIATRY

Increased Body Weight and Fat Mass After Subchronic GIP Receptor Antagonist, but Not GLP-2 Receptor Antagonist, Administration in Rats

(2019) Sara Baldassano et al.   Frontiers in Endocrinology

M3 muscarinic receptor activation reduces hepatocyte lipid accumulation via CaMKKβ/AMPK pathway

(2019) Ravirajsinh N. Jadeja et al.   BIOCHEMICAL PHARMACOLOGY

The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD)

(2019) Sravan K. Thondam et al.   PEPTIDES

Blockade of multiple monoamines receptors reduce insulin secretion from pancreatic β-cells

(2019) Mao Nagata et al.   Scientific Reports

Second-Generation Antipsychotics and Dysregulation of Glucose Metabolism: Beyond Weight Gain

(2019) Diana Grajales et al.   Cells

Serotonergic regulation of insulin secretion

(2018) L. R. Cataldo Bascuñan et al.   Acta Physiologica

Antipsychotics and glucose metabolism: how brain and body collide

(2018) Chantel Kowalchuk et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Dopamine D2 Receptors Dimers: How can we Pharmacologically Target Them?

(2018) Marco Carli et al.   Current Neuropharmacology

Distinctive binding properties of the negative allosteric modulator, [ 3 H]SB269,652, at recombinant dopamine D 3 receptors

(2018) Irene Fasciani et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences

(2018) Stefano Aringhieri et al.   PHARMACOLOGY & THERAPEUTICS

Possible Pharmacodynamic and Pharmacokinetic Drug-Drug Interactions That Are Likely to Be Clinically Relevant and/or Frequent in Bipolar Disorder

(2018) Jose de Leon et al.   Current Psychiatry Reports

Metabolic Effects of Antipsychotics on Adiposity and Insulin Sensitivity in Youths

(2018) Ginger E. Nicol et al.   JAMA Psychiatry

Contribution of parasympathetic muscarinic augmentation of insulin secretion to olanzapine-induced hyperinsulinemia

(2018) Michael R. Rickels et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Ghrelin, a gastrointestinal hormone, regulates energy balance and lipid metabolism

(2018) You Lv et al.   BIOSCIENCE REPORTS

The IRS/PI3K/Akt signaling pathway mediates olanzapine-induced hepatic insulin resistance in male rats

(2018) Liying Ren et al.   LIFE SCIENCES

Clozapine as the most efficacious antipsychotic for activating ERK 1/2 kinases: Role of 5-HT 2A receptor agonism

(2017) Stefano Aringhieri et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

The First Negative Allosteric Modulator for Dopamine D 2 and D 3 Receptors, SB269652 May Lead to a New Generation of Antipsychotic Drugs

(2017) Mario Rossi et al.   MOLECULAR PHARMACOLOGY

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

(2017) C. Hiemke et al.   PHARMACOPSYCHIATRY

Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder

(2017) Julie R. Larsen et al.   JAMA Psychiatry

Leptin Resistance and the Neuro-Adipose Connection

(2017) Andreia Barateiro et al.   Frontiers in Endocrinology

Antipsychotic Drugs: From Receptor-binding Profiles to Metabolic Side Effects

(2017) Spyridon Siafis et al.   Current Neuropharmacology

Prolonged Activation of the Htr2b Serotonin Receptor Impairs Glucose Stimulated Insulin Secretion and Mitochondrial Function in MIN6 Cells

(2017) Luis Rodrigo Cataldo et al.   PLoS One

Involvement of the leptin-adiponectin axis in inflammation and oxidative stress in the metabolic syndrome

(2017) Gema Frühbeck et al.   Scientific Reports

Pharmacogenetics of clozapine response and induced weight gain: A comprehensive review and meta-analysis

(2016) Florence Gressier et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

A Naturalistic Randomized Placebo-Controlled Trial of Extended-Release Metformin to Prevent Weight Gain Associated With Olanzapine in a US Community-Dwelling Population

(2016) Jeffrey Rado et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes

(2016) Karla Mayfield et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Histamine receptor signaling in energy homeostasis

(2016) Iustin V. Tabarean   NEUROPHARMACOLOGY

Evaluating an individualized lifestyle and life skills intervention to prevent antipsychotic-induced weight gain in first-episode psychosis

(2015) Jackie Curtis et al.   Early Intervention in Psychiatry

Antipsychotics-induced metabolic alterations: Focus on adipose tissue and molecular mechanisms

(2015) Pedro Gonçalves et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Novel dimensions of D3 receptor function: Focus on heterodimerisation, transactivation and allosteric modulation

(2015) Roberto Maggio et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Neurotransmitters and Neuropeptides: New Players in the Control of Islet of Langerhans' Cell Mass and Function

(2015) Eliana S. Di Cairano et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Altered serotonin (5-HT) 1D and 2A receptor expression may contribute to defective insulin and glucagon secretion in human type 2 diabetes

(2015) H. Bennet et al.   PEPTIDES

Metabolic syndrome and obesity among users of second generation antipsychotics: A global challenge for modern psychopharmacology

(2015) Leonel E. Rojo et al.   PHARMACOLOGICAL RESEARCH

Metabolic Disturbances Independent of Body Mass in Patients with Schizophrenia Taking Atypical Antipsychotics

(2015) Shi Hyun Kang et al.   Psychiatry Investigation

A potential mechanism underlying atypical antipsychotics-induced lipid disturbances

(2015) H L Cai et al.   Translational Psychiatry

“First do no harm.” A systematic review of the prevalence and management of antipsychotic adverse effects

(2014) Su Ling Young et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Clozapine Acts as an Agonist at Serotonin 2A Receptors to Counter MK-801-Induced Behaviors through a βArrestin2-Independent Activation of Akt

(2014) Cullen L Schmid et al.   NEUROPSYCHOPHARMACOLOGY

Betahistine ameliorates olanzapine-induced weight gain through modulation of histaminergic, NPY and AMPK pathways

(2014) Jiamei Lian et al.   PSYCHONEUROENDOCRINOLOGY

Molecular pathophysiology of metabolic effects of antipsychotic medications

(2014) Jacob S. Ballon et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Sustained Weight Loss After Treatment With a Glucagon-Like Peptide-1 Receptor Agonist in an Obese Patient With Schizophrenia and Type 2 Diabetes

(2013) Pelle L. Ishøy et al.   AMERICAN JOURNAL OF PSYCHIATRY

Second Generation Antipsychotic-Induced Type 2 Diabetes: A Role for the Muscarinic M3 Receptor

(2013) Katrina Weston-Green et al.   CNS DRUGS

Antipsychotic-Induced Insulin Resistance and Postprandial Hormonal Dysregulation Independent of Weight Gain or Psychiatric Disease

(2013) Karen L. Teff et al.   DIABETES

Effects of Adjunctive Metformin on Metabolic Traits in Nondiabetic Clozapine-Treated Patients With Schizophrenia and the Effect of Metformin Discontinuation on Body Weight

(2013) Chun-Hsin Chen et al.   JOURNAL OF CLINICAL PSYCHIATRY

Estimating Dopamine D2 Receptor Occupancy for Doses of 8 Antipsychotics

(2013) Irene M. Lako et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

(2013) Stefan Leucht et al.   LANCET

Minireview: Dopaminergic Regulation of Insulin Secretion from the Pancreatic Islet

(2013) Alessandro Ustione et al.   MOLECULAR ENDOCRINOLOGY

Serotonin Receptor 2C and Insulin Secretion

(2013) Qiang Zhang et al.   PLoS One

Metabolic Side-Effects of the Novel Second-Generation Antipsychotic Drugs Asenapine and Iloperidone: A Comparison with Olanzapine

(2013) Heidi N. Boyda et al.   PLoS One

Update on Typical and Atypical Antipsychotic Drugs

(2012) Herbert Y. Meltzer   Annual Review of Medicine

Mortality and guideline-concordant care for older patients with schizophrenia: a retrospective longitudinal study

(2012) Jack Y Tsan et al.   BMC Medicine

Health promotion lifestyle interventions for weight management in psychosis: a systematic review and meta-analysis of randomised controlled trials

(2012) Elena Bonfioli et al.   BMC Psychiatry

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

Epinephrine deficiency results in intact glucose counter-regulation, severe hepatic steatosis and possible defective autophagy in fasting mice

(2012) Rana I. Sharara-Chami et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Fatty acids-stress attenuates gluconeogenesis induction and glucose production in primary hepatocytes

(2012) Noga Budick-Harmelin et al.   Lipids in Health and Disease

Dopamine-Mediated Autocrine Inhibitory Circuit Regulating Human Insulin Secretionin Vitro

(2012) Norman Simpson et al.   MOLECULAR ENDOCRINOLOGY

Insulin secretion in patients receiving clozapine, olanzapine, quetiapine and risperidone

(2012) Peter Manu et al.   SCHIZOPHRENIA RESEARCH

Atypical antipsychotic drugs perturb AMPK-dependent regulation of hepatic lipid metabolism

(2011) Kyoung-Jin Oh et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose?

(2011) Marianne Ulcickas Yood et al.   BMC Psychiatry

Convergence of the Insulin and Serotonin Programs in the Pancreatic  -Cell

(2011) Y. Ohta et al.   DIABETES

AMP-activated protein kinase is activated in adipose tissue of individuals with type 2 diabetes treated with metformin: a randomised glycaemia-controlled crossover study

(2011) J. G. Boyle et al.   DIABETOLOGIA

Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status

(2011) X. Stephenne et al.   DIABETOLOGIA

Topiramate-induced weight loss: A review

(2011) Alberto Verrotti et al.   EPILEPSY RESEARCH

l-Tryptophan-mediated Enhancement of Susceptibility to Nonalcoholic Fatty Liver Disease Is Dependent on the Mammalian Target of Rapamycin

(2011) Yosuke Osawa et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Glycine reuptake inhibitor RG1678: A pharmacologic characterization of an investigational agent for the treatment of schizophrenia

(2011) Daniela Alberati et al.   NEUROPHARMACOLOGY

PharmGKB summary

(2011) Caroline F. Thorn et al.   Pharmacogenetics and Genomics

The Physiology, Signaling, and Pharmacology of Dopamine Receptors

(2011) J.-M. Beaulieu et al.   PHARMACOLOGICAL REVIEWS

Olanzapine-Induced Hyperphagia and Weight Gain Associate with Orexigenic Hypothalamic Neuropeptide Signaling without Concomitant AMPK Phosphorylation

(2011) Johan Fernø et al.   PLoS One

A Double Blind, Placebo-Controlled, Randomized Crossover Study of the Acute Metabolic Effects of Olanzapine in Healthy Volunteers

(2011) Vance L. Albaugh et al.   PLoS One

Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat

(2011) Goran Jassim et al.   PSYCHOPHARMACOLOGY

Association of genetic variants of the histamine H1 and muscarinic M3 receptors with BMI and HbA1c values in patients on antipsychotic medication

(2011) Jelle Vehof et al.   PSYCHOPHARMACOLOGY

Life expectancy among persons with schizophrenia or bipolar affective disorder

(2011) Thomas Munk Laursen   SCHIZOPHRENIA RESEARCH

Histamine Regulation in Glucose and Lipid Metabolism via Histamine Receptors

(2010) Ke-Yong Wang et al.   AMERICAN JOURNAL OF PATHOLOGY

Treatment with antipsychotics and the risk of diabetes in clinical practice

(2010) Lars Vedel Kessing et al.   BRITISH JOURNAL OF PSYCHIATRY

Management of antipsychotic-related weight gain

(2010) Lawrence Maayan et al.   Expert Review of Neurotherapeutics

Lipid and C-Reactive Protein Levels, Cardiovascular Disease Risk Factors and Simvastatin Treatment in Brazilian Individuals

(2010) Alexandre B. Rosendo et al.   INFLAMMATION

Association of Weight Gain and Metabolic Syndrome in Patients Taking Clozapine

(2010) Ya Mei Bai et al.   JOURNAL OF CLINICAL PSYCHIATRY

A Serotonin and Melanocortin Circuit Mediates D-Fenfluramine Anorexia

(2010) Y. Xu et al.   JOURNAL OF NEUROSCIENCE

Increased Food Intake and Energy Expenditure Following Administration of Olanzapine to Healthy Men

(2010) Robert J. Fountaine et al.   Obesity

Brain serotonin system in the coordination of food intake and body weight

(2010) Daniel D. Lam et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis

(2010) Christine Rummel-Kluge et al.   SCHIZOPHRENIA RESEARCH

Novel insights into the function of β-cell M3 muscarinic acetylcholine receptors: therapeutic implications

(2010) Inigo Ruiz de Azua et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with Schizophrenia

(2009) D. C. Henderson et al.   ACTA PSYCHIATRICA SCANDINAVICA

Regulation of PKD by the MAPK p38δ in Insulin Secretion and Glucose Homeostasis

(2009) Grzegorz Sumara et al.   CELL

Hepatic Muscarinic Acetylcholine Receptors Are Not Critically Involved in Maintaining Glucose Homeostasis in Mice

(2009) Jian H. Li et al.   DIABETES

Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes

(2009) Bo Ahrén   NATURE REVIEWS DRUG DISCOVERY

The 'atypicality' of antipsychotics: a concept re-examined and re-defined

(2009) Gerhard Gründer et al.   NATURE REVIEWS DRUG DISCOVERY

Metabolic side effects of antipsychotic drug treatment – pharmacological mechanisms

(2009) Gavin P Reynolds et al.   PHARMACOLOGY & THERAPEUTICS

Rosiglitazone in the Assistance of Metabolic Control during Olanzapine Administration in Schizophrenia: A Pilot Double-blind, Placebo-controlled, 12-week Trial

(2009) T. Baptista et al.   PHARMACOPSYCHIATRY

AMPK in Health and Disease

(2009) Gregory R. Steinberg et al.   PHYSIOLOGICAL REVIEWS

Weight gain with clozapine: 8-year cohort naturalistic study among hospitalized Chinese schizophrenia patients

(2009) Ya-Mei Bai et al.   SCHIZOPHRENIA RESEARCH

Extended release metformin for metabolic control assistance during prolonged clozapine administration: A 14 week, double-blind, parallel group, placebo-controlled study

(2009) Edgardo Carrizo et al.   SCHIZOPHRENIA RESEARCH

Metformin Addition Attenuates Olanzapine-Induced Weight Gain in Drug-Naive First-Episode Schizophrenia Patients: A Double-Blind, Placebo-Controlled Study

(2008) Ren-Rong Wu et al.   AMERICAN JOURNAL OF PSYCHIATRY

Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia

(2008) Olga O. Yevtushenko et al.   BRITISH JOURNAL OF PSYCHIATRY

Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat

(2008) G. C. Smith et al.   DIABETOLOGIA

Insulin sensitivity: modulation by nutrients and inflammation

(2008) Simon Schenk et al.   JOURNAL OF CLINICAL INVESTIGATION

Catecholamine-induced lipolysis in adipose tissue and skeletal muscle in obesity

(2008) Johan W.E. Jocken et al.   PHYSIOLOGY & BEHAVIOR

Schizophrenia, Obesity, and Antipsychotic Medications: What Can We Do?

(2008) Leslie Citrome et al.   POSTGRADUATE MEDICINE

Differential Effects of Various Typical and Atypical Antipsychotics on Plasma Glucose and Insulin Levels in the Mouse: Evidence for the Involvement of Sympathetic Regulation

(2008) Y. E. Savoy et al.   SCHIZOPHRENIA BULLETIN

The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance

(2008) Kirsten Lykkegaard et al.   SCHIZOPHRENIA RESEARCH